(Reuters) – Johnson & Johnson on Wednesday posted a 32% rise in fourth-quarter profit, boosted by demand for its cancer drugs Darzalex and Imbruvica.

The company’s net earnings rose to $4.01 billion, or $1.50 per share, in the quarter, from $3.04 billion, or $1.12 per share, a year earlier.

Total sales rose to 1.7% to $20.75 billion.

Reporting by Manas Mishra and Saumya Sibi Joseph in Bengaluru; Editing by Saumyadeb Chakrabarty


Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Bitcoin surges above $15,000 and is closing in on record

New York (CNN Business)Bitcoin soared more than 7% Thursday and was trading above $15,000 — its highest level in nearly three years — as mainstream interest in the cryptocurrency builds and the US dollar weakens. The value of one bitcoin…

Japan’s pandemic woes unravel benefits of ‘Abenomics’

TOKYO (Reuters) – Japanese Prime Minister Shinzo Abe’s rise to power in 2012 ushered in bold policies known as “Abenomics” that helped revive the economy and boost corporate profits, exports and jobs. However, the record plunge in Japan’s economy in…

Trump tries to shift blame as virus outbreak rattles markets

WASHINGTON — As global markets plunged amid growing fears about the coronavirus outbreak, President Donald Trump and his allies pulled from a familiar playbook Friday and blamed others for the slide. It’s a challenging sell for a president who has…

Rich world pumps aid to fight coronavirus, epicenter Europe reels

LONDON/BEIJING (Reuters) – The world’s wealthiest nations poured unprecedented aid into the traumatized global economy on Thursday as coronavirus cases ballooned in the current epicenter Europe even as they waned at the pandemic’s point of origin, China. With almost 228,000…